Not logged in.png)
Share.png)
SaveImpact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancer
Okemoto, D.; Nakayama, I.; Jubashi, A.; Sakamoto, N.; Okunaka, M.; Matsubara, V.; Miyashita, V.; Kobayashi, A.; Okazaki, U.; Vamamoto, K.; Seguchi, K.; Hosokai, T.; Ogura, T.; Mishima, S.; Kotani, D.; Kawazoe, A.; Hashimoto, T.; Kuboki, V.; Bando, H.; Kojima, T.; Voshino, T.; Kuwata, T.; Vamaguchi, T.; Nishikawa, H.; Shitara, K. Share Save A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumorsKondo, S.; Koyama, T.; Kawazoe, A.; Iwasa, S.; Yonemori, K.; Shitara, K.; Nakamura, Y.; Saori, M.; Yamamoto, N.; Sato, J.; Sahara, T.; Hayata, N.; Yamamuro, S.; Kimura, T.; Dutta, L.; Tamai, T.; Ikeda, M. Share Save Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalationTamura, K.; Shitara, K.; Naito, Y.; Shimomura, A.; Fujiwara, Y.; Yonemori, K.; Shimizu, C.; Shimoi, T.; Kuboki, Y.; Matsubara, N.; Kitano, A.; Jikoh, T.; Fujisaki, Y.; Yver, A.; Doi, T. Share Save 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
